Sanofi raises 2026 earnings guidance after third-quarter sales of €14,444 million
FROM THE WIRE · FINANCE.YAHOO.COM
Sanofi reported third quarter 2026 sales of €14,444 million and net income of €3,021 million, and raised full year 2026 earnings guidance while projecting low teens % sales growth and mid teens % business EPS growth at constant exchange rates. The firm is shaping its portfolio…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishAn raised earnings guidance from a large pharma group is relevant for the healthcare sector and European equities.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Sanofi reported third-quarter 2026 sales of €14,444 million and net income of €3,021 million.
- 02The company raised full-year 2026 earnings guidance and projects low-teens sales growth.
- 03Sanofi discontinued the SAR448272 oral STAT6 degrader and advances a Phase 3 flu-COVID combination vaccine with Novavax.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Sanofi47.47 USDMarket closedtoday +4.72%Positive Novavax, Inc.10.65 USDMarket closedtoday +10.02%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets